Rottneros’ interim report January–September 2026

EBITDA improved by 47 MSEK to 26 MSEK from -21 MSEK, with the company attributing the improvement to cost focus and lower variable costs. Net turnover was 570 MSEK versus 574 MSEK; sales volume and currency were slightly higher than in Q3 2025, while sales prices were slightly lower. NBSK prices in SEK were 1% below Q3 2025, while CTMP prices were 5% higher; versus Q2 2026, NBSK rose 1% and CTMP 4%.

Analysis

Cost-led recovery, not yet a pricing-led turn. The implied EBITDA margin is about 4.6%, but revenue is essentially flat and NBSK pricing remains a headwind; the improvement therefore needs validation as repeatable rather than a one-quarter benefit from variable-cost reductions. The key second-order exposure is operating leverage: if pulp prices weaken or production/input costs rise, a modest margin base can erase the improvement quickly. CTMP strength is a useful offset, but does not establish broad-based pricing power across grades.

Over the next 1–3 months, monitor realized NBSK and CTMP prices in SEK, volumes, and whether cost savings persist without sacrificing output or maintenance. FX may cushion or amplify reported SEK realizations, so separate underlying price from currency. Over 6–18 months, sustained margin recovery would require either better market pricing or durable structural cost reductions; neither is established here. A reversal in input-cost relief or weaker pulp demand is the principal downside. Falsification of the recovery thesis: EBITDA slips back toward breakeven despite stable volumes, or management indicates the savings were temporary. With no issuer identity, valuation, or share-price context supplied, there is insufficient basis for a security-specific directional trade.

Key Decisions for Investors

• Treat the result as a monitoring signal, not confirmation of a cyclical earnings recovery; avoid extrapolating the EBITDA rebound until it is sustained in another reporting period.
• For pulp-sector exposure, favor producers with demonstrably lower cash costs over higher-cost peers if NBSK prices soften; do not infer this issuer’s relative cost position from the release.
• Track SEK NBSK and CTMP realizations, volume, and cash-cost guidance over the next quarter. Reassess positively if margin gains persist alongside stable volumes; turn cautious if EBITDA weakens despite stable or improving realizations.
• No issuer-specific trade is warranted from the available information. Verify the company identity, production mix, cost bridge, and market valuation before sizing a position.